The study evaluated the efficacy and safety of adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy for patients with acute myeloid leukemia (AML) and a FLT3 mutation. The phase 3 trial, conducted by the Cancer and Leukemia Group B (CALGB) 10603 (RATIFY) study, included 717 patients aged 18 to 59 years with newly diagnosed AML and FLT3 mutations. Patients were randomly assigned to receive standard chemotherapy plus either midostaurin or placebo. The primary endpoint was overall survival, and secondary endpoints included event-free survival and complete remission rates. Results showed that the addition of midostaurin significantly prolonged overall survival and event-free survival compared to placebo, with a hazard ratio for death of 0.78 (P=0.009) and a hazard ratio for event or death of 0.78 (P=0.002). The benefit was consistent across different FLT3 subtypes. Adverse events were similar between the two groups, with no unexpected issues. The study concluded that midostaurin, when added to standard chemotherapy, improved outcomes in patients with AML and a FLT3 mutation.The study evaluated the efficacy and safety of adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy for patients with acute myeloid leukemia (AML) and a FLT3 mutation. The phase 3 trial, conducted by the Cancer and Leukemia Group B (CALGB) 10603 (RATIFY) study, included 717 patients aged 18 to 59 years with newly diagnosed AML and FLT3 mutations. Patients were randomly assigned to receive standard chemotherapy plus either midostaurin or placebo. The primary endpoint was overall survival, and secondary endpoints included event-free survival and complete remission rates. Results showed that the addition of midostaurin significantly prolonged overall survival and event-free survival compared to placebo, with a hazard ratio for death of 0.78 (P=0.009) and a hazard ratio for event or death of 0.78 (P=0.002). The benefit was consistent across different FLT3 subtypes. Adverse events were similar between the two groups, with no unexpected issues. The study concluded that midostaurin, when added to standard chemotherapy, improved outcomes in patients with AML and a FLT3 mutation.